OrthoPediatrics Corp. Expands Scoliosis Portfolio with Launch of VerteGlide™ System
OrthoPediatrics (Nasdaq: KIDS) has announced the U.S. launch of the VerteGlide Spinal Growth Guidance System, marking their 80th system for treating pediatric musculoskeletal conditions. The system, recently FDA-cleared, is designed to treat Early Onset Scoliosis (EOS) in children under 10 years old who often experience pulmonary and digestive dysfunction.
The VerteGlide system aims to correct deformity while minimizing repeat surgeries until skeletal maturity. Initial surgeries are expected to begin at select children's centers during summer 2025. The technology was developed in partnership with pediatric orthopedic surgeons Dr. Richard McCarthy and Dr. Scott Luhmann, utilizing Shilla™ technology licensed from Medtronic.
OrthoPediatrics (Nasdaq: KIDS) ha annunciato il lancio negli Stati Uniti del VerteGlide Spinal Growth Guidance System, segnando il loro ottantesimo sistema per il trattamento delle condizioni muscoloscheletriche pediatriche. Il sistema, recentemente approvato dalla FDA, è progettato per trattare la Scoliosi Iniziale (EOS) nei bambini di età inferiore ai 10 anni, che spesso sperimentano disfunzioni polmonari e digestive.
Il sistema VerteGlide mira a correggere la deformità riducendo al minimo le chirurgie ripetute fino al raggiungimento della maturità scheletrica. Si prevede che le chirurgie iniziali inizieranno in alcuni centri pediatrici selezionati nell'estate del 2025. La tecnologia è stata sviluppata in collaborazione con i chirurghi ortopedici pediatrici Dr. Richard McCarthy e Dr. Scott Luhmann, utilizzando la tecnologia Shilla™ concessa in licenza da Medtronic.
OrthoPediatrics (Nasdaq: KIDS) ha anunciado el lanzamiento en EE. UU. del VerteGlide Spinal Growth Guidance System, marcando su octavo sistema para tratar condiciones musculoesqueléticas pediátricas. El sistema, recientemente aprobado por la FDA, está diseñado para tratar la Escoliosis de Inicio Temprano (EOS) en niños menores de 10 años que a menudo experimentan disfunciones pulmonares y digestivas.
El sistema VerteGlide tiene como objetivo corregir la deformidad mientras minimiza las cirugías repetidas hasta que se alcance la madurez esquelética. Se espera que las cirugías iniciales comiencen en centros pediátricos seleccionados durante el verano de 2025. La tecnología fue desarrollada en asociación con los cirujanos ortopédicos pediátricos Dr. Richard McCarthy y Dr. Scott Luhmann, utilizando la tecnología Shilla™ licenciada de Medtronic.
OrthoPediatrics (Nasdaq: KIDS)는 VerteGlide Spinal Growth Guidance System의 미국 출시를 발표하며, 소아 근골격계 질환 치료를 위한 80번째 시스템을 선보입니다. 최근 FDA 승인을 받은 이 시스템은 10세 이하의 어린이에서 조기 발병 척추측만증 (EOS)을 치료하기 위해 설계되었으며, 이들은 종종 호흡기 및 소화기 기능 장애를 겪습니다.
VerteGlide 시스템은 골격 성숙이 이루어질 때까지 반복 수술을 최소화하면서 기형을 교정하는 것을 목표로 합니다. 초기 수술은 2025년 여름 동안 일부 아동 센터에서 시작될 예정입니다. 이 기술은 소아 정형외과 의사인 Dr. Richard McCarthy와 Dr. Scott Luhmann과 협력하여 개발되었으며, Medtronic으로부터 라이센스 받은 Shilla™ 기술을 활용하고 있습니다.
OrthoPediatrics (Nasdaq: KIDS) a annoncé le lancement aux États-Unis du VerteGlide Spinal Growth Guidance System, marquant leur 80ème système pour traiter les conditions musculosquelettiques pédiatriques. Le système, récemment approuvé par la FDA, est conçu pour traiter la Scoliose de Début Précoce (EOS) chez les enfants de moins de 10 ans, qui souffrent souvent de dysfonctionnements pulmonaires et digestifs.
Le système VerteGlide vise à corriger les déformations tout en minimisant les interventions chirurgicales répétées jusqu'à la maturité squelettique. Les premières opérations devraient commencer dans certains centres pour enfants sélectionnés durant l'été 2025. La technologie a été développée en partenariat avec les chirurgiens orthopédiques pédiatriques Dr. Richard McCarthy et Dr. Scott Luhmann, utilisant la technologie Shilla™ sous licence de Medtronic.
OrthoPediatrics (Nasdaq: KIDS) hat die Einführung des VerteGlide Spinal Growth Guidance System in den USA angekündigt, was ihr 80. System zur Behandlung pädiatrischer muskuloskeletaler Erkrankungen markiert. Das System, das kürzlich von der FDA genehmigt wurde, ist darauf ausgelegt, Frühkindliche Skoliose (EOS) bei Kindern unter 10 Jahren zu behandeln, die häufig Atem- und Verdauungsstörungen aufweisen.
Das VerteGlide-System zielt darauf ab, Deformitäten zu korrigieren und wiederholte Operationen bis zur skeletalen Reife zu minimieren. Die ersten Operationen werden voraussichtlich im Sommer 2025 in ausgewählten Kinderzentren beginnen. Die Technologie wurde in Zusammenarbeit mit den pädiatrischen Orthopäden Dr. Richard McCarthy und Dr. Scott Luhmann entwickelt und nutzt die von Medtronic lizenzierte Shilla™-Technologie.
- FDA clearance obtained for VerteGlide System
- Product expansion into Early Onset Scoliosis treatment market
- Partnership with established medical technology company Medtronic through licensing agreement
- initial launch may restrict immediate revenue potential
- Dependence on licensed technology from Medtronic
Insights
The VerteGlide Spinal Growth Guidance System represents a significant advancement in the treatment of Early Onset Scoliosis (EOS), a condition that has historically presented substantial clinical challenges. The guided growth technology addresses the fundamental challenge in pediatric spinal instrumentation – allowing for deformity correction while accommodating a child's natural growth without requiring frequent surgical interventions.
The system's ability to minimize repeat surgeries until skeletal maturity delivers dual benefits: reduced patient trauma and lower healthcare costs. For children under 10 suffering from the pulmonary and digestive dysfunction associated with EOS, this represents a meaningful clinical advancement that could improve quality of life and potentially long-term outcomes.
The FDA clearance and measured rollout approach demonstrate appropriate regulatory and clinical caution. Having key opinion leaders like Drs. McCarthy and Luhmann involved in development suggests strong clinical input and increases the likelihood of adoption in specialized pediatric centers. This system being OrthoPediatrics' 80th product underscores their comprehensive approach to pediatric orthopedics.
The Medtronic licensing arrangement for Shilla technology shows strategic partnership capabilities that complement internal innovation. This represents OrthoPediatrics' second EOS-focused technology, indicating a systematic approach to addressing this particularly challenging condition rather than one-off product development.
This product launch strengthens OrthoPediatrics' position as the dominant pure-play in pediatric orthopedics, a specialized market segment where focused expertise creates competitive advantages. While the immediate revenue impact from the VerteGlide system will likely be modest due to the controlled summer rollout at select centers, the strategic implications are more substantial.
The EOS market represents a high-value segment within pediatric orthopedics due to the condition's severity and complexity. Technologies that reduce repeat surgeries can command premium pricing while simultaneously improving hospital economics by reducing lifetime treatment costs. This value proposition typically supports healthy margins even with specialized, lower-volume products.
The FDA clearance de-risks the commercialization pathway, while the partnership with recognized physician thought leaders should accelerate clinical adoption. Being OrthoPediatrics' 80th system demonstrates portfolio depth that reinforces the company's specialized sales channel strategy and creates barriers to entry for potential competitors.
The Medtronic licensing arrangement shows pragmatic resource allocation – leveraging external technology where appropriate while maintaining focus on proprietary developments. This being the second in a series of EOS technologies indicates continued R&D investment in addressing unmet needs in this therapeutic area, suggesting a robust pipeline that supports long-term growth beyond this single product launch.
WARSAW, Ind., April 08, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the U.S. launch of the new VerteGlide Spinal Growth Guidance System, used to treat Early Onset Scoliosis (“EOS”). This represents the company’s 80th system designed to treat musculoskeletal issues in children.
VerteGlide is a guided growth technology designed for children with Early Onset Scoliosis, a severe and sometimes life-threatening condition affecting kids under the age of 10, who often suffer from pulmonary and digestive dysfunction because of the deformity. VerteGlide represents the second in a series of technologies OrthoPediatrics is developing to address the challenges of this special group of children suffering from debilitating and life-threatening consequences of Early Onset Scoliosis. With its unique design, the VerteGlide Spinal Growth Guidance System is designed to allow for deformity correction and minimize repeat surgeries needed until skeletal maturity. With the recent FDA clearance of this device, the Company is preparing for a limited launch and expects to be doing initial surgeries with select children's centers during summer of this year.
Dr. Richard McCarthy, a pediatric orthopedic spine surgeon in Louisville, Kentucky is a pioneer in the field of growth guidance in scoliosis surgery; he and Dr. Scott Luhmann of St. Louis have been instrumental in partnering with the Company on the design and development of the system. McCarthy shared that "VerteGlide marks a breakthrough in technology for children."
OrthoPediatrics Scoliosis division President, Greg Odle commented “We are excited to introduce another new product to treat children with EOS. The team has been working with key opinion leaders from the surgeon community to identify new technologies that will help this particularly vulnerable patient population. VerteGlide’s launch represents our commitment to treating the entire disease state of scoliosis.”
CEO, David Bailey echoed those comments, saying “I’m incredibly proud of the Engineering team and the work the business teams have done to bring this product to market. It feels like we are making meaningful progress in providing healthcare professionals innovative treatment options for the patients they serve.”
The VerteGlide Spinal Growth Guidance System is made possible with the Shilla™ technology licensed from Medtronic.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406
FAQ
What is the VerteGlide System launched by OrthoPediatrics (KIDS)?
When will OrthoPediatrics (KIDS) begin surgeries with the VerteGlide System?
How many medical systems has OrthoPediatrics (KIDS) developed?
Which doctors collaborated on developing OrthoPediatrics' VerteGlide System?
